SEC Form 4 · accession 0001140361-18-000921
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
V Bryan Lawlis
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 8:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 2, 2018 | M | 3,750 | $38.59 | A | 18,610 | D | |
| Common StockF1,F3,F2 | Jan 2, 2018 | S | 3,750 | $88.84 | D | 14,860 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1,F4 | $38.59 | Jan 2, 2018 | M | 3,750 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 3,750 | 3,750 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.
- F2Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 1,050 shares as previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017.
- F3All shares sold at the same price.
- F4Reflects the number of stock options outstanding after the transaction from this specific stock option grant.